What Nuvalent, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 141 |
| Total trades | 0 | 246 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 246 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Protopapas Anna | Director | Jul 15 | Disposition to Issuer · D Class A Common Stock - Restricted Stock Units | −3,444 | — | — | 0 |
| Protopapas Anna | Director | Jul 15 | Tender Offer · U NUVL | −5,146 | $124.00 | −$638K | 0 |
| Meyers Michael L. | Director | Jul 15 | Disposition to Issuer · D Class A Common Stock - Restricted Stock Units | −3,444 | — | — | 0 |
| Meyers Michael L. | Director | Jul 15 | Tender Offer · U NUVL | −5,146 | $124.00 | −$638K | 0 |
| Srivastava Sapna | Director | Jul 15 | Disposition to Issuer · D Class A Common Stock - Restricted Stock Units | −3,444 | — | — | 0 |
| Srivastava Sapna | Director | Jul 15 | Tender Offer · U NUVL | −5,146 | $124.00 | −$638K | 0 |
| Noci Darlene | Chief Development Officer | Jul 15 | Disposition to Issuer · D Class A Common Stock - Performance Stock Units | −14,350 | — | — | 0 |
| Noci Darlene | Chief Development Officer | Jul 15 | Grant / award · A Class A Common Stock - Performance Stock Units | +14,350 | — | — | 14,350 |
| Noci Darlene | Chief Development Officer | Jul 15 | Disposition to Issuer · D Class A Common Stock - Restricted Stock Units | −41,100 | — | — | 0 |
| Noci Darlene | Chief Development Officer | Jul 15 | Tender Offer · U NUVL | −17,017 | $124.00 | −$2.11M | 0 |
| Squarer Ron | Director | Jul 15 | Disposition to Issuer · D Class A Common Stock - Restricted Stock Units | −6,281 | — | — | 0 |
| Turner Christopher Durant | Chief Medical Officer | Jul 15 | Disposition to Issuer · D Class A Common Stock - Performance Stock Units | −14,350 | — | — | 0 |
| Turner Christopher Durant | Chief Medical Officer | Jul 15 | Grant / award · A Class A Common Stock - Performance Stock Units | +14,350 | — | — | 14,350 |
| Turner Christopher Durant | Chief Medical Officer | Jul 15 | Disposition to Issuer · D Class A Common Stock - Restricted Stock Units | −41,100 | — | — | 0 |
| Turner Christopher Durant | Chief Medical Officer | Jul 15 | Tender Offer · U NUVL | −31,530 | $124.00 | −$3.91M | 0 |
| Balcom Alexandra | Chief Financial Officer | Jul 15 | Disposition to Issuer · D Class A Common Stock - Performance Stock Units | −14,350 | — | — | 0 |
| Balcom Alexandra | Chief Financial Officer | Jul 15 | Grant / award · A Class A Common Stock - Performance Stock Units | +14,350 | — | — | 14,350 |
| Balcom Alexandra | Chief Financial Officer | Jul 15 | Disposition to Issuer · D Class A Common Stock - Restricted Stock Units | −41,100 | — | — | 0 |
| Balcom Alexandra | Chief Financial Officer | Jul 15 | Tender Offer · U NUVL | −44,433 | $124.00 | −$5.51M | 0 |
| Wheeler Cameron | Director | Jul 15 | Disposition to Issuer · D Class A Common Stock - Restricted Stock Units | −3,444 | — | — | 0 |
Loading...